BridgeBio Pharma Has Lost 28% Since July: Barclays Sees 139% Upside
BridgeBio Pharma (BBIO) closed at $65.35 on Oct. 9, down 28% from its July high. Barclays reaffirmed its Overweight rating and $156 target, implying 139% upside. The company reported wider-than-expected Q2 losses and shrinking patient switch pool for Attruby, despite $222.4M in U.S. sales. The FDA's Nov. 27 decision on BBP-418 is a key upcoming event.
How this was made
The 30-second read
Why it matters
The earnings miss pressures the stock, but the high target suggests potential upside on future milestones.
Market read
Earnings miss with analyst coverage; modest trading relevance.
What to watch
Upcoming FDA decision on BBIO‑418 on Nov 27 could reverse the current negative sentiment.
Background
BridgeBio Pharma's Q2 results showed a loss wider than expected and a shrinking pool of patients switching from a Pfizer drug, while analyst Barclays maintains a high price target.
Ticker impact
BridgeBio Pharma reported a wider-than-expected Q2 loss and shrinking patient pool, prompting analyst coverage and a high price target.
likely pressure as the market prices in the wider loss and shrinking switch patient pool
Loss of $0.78 per share exceeds expectations and the commercial outlook is uncertain, outweighing the bullish target.
Market effects
Biotech sector may see heightened scrutiny on patient‑pool dynamics.
US biotech investors may adjust exposure to similar pipeline companies.
Limited to investors tracking US biotech earnings.
Counterpoint
Barclays' 139% upside target implies significant upside if FDA approval for BBIO‑418 materializes.
Key entities
- companyBridgeBio Pharma
Biotech firm reporting Q2 results.
